Decoding Metabolic Clinical Trial Landscape
Highlights from “Decoding Metabolic Clinical Trial Landscape,” a white paper by the Novo Nordisk Malaysia Clinical Development Centre, July 2026.
Southeast Asia is facing a rising tide of obesity, type 2 diabetes, and related metabolic disease — and Malaysia sits at the centre of that story. A new industry white paper points to Malaysia as a strategic contributor to the next generation of metabolic clinical trials, citing a combination of disease burden, national coordination, and a maturing research ecosystem.